Skip to content

Study · Not a test of the peptide alone · 2022

6 results

Efficient transdermal delivery of functional protein cargoes by a hydrophobic peptide MTD 1067.

Shin HJ, Bak SU, La HN, Kang JS, Lee HH, Eom HJ, Lee BK, Kang HA

Scientific reports27 Jun 2022Cited by 9 (Europe PMC)

PMID35760980 (opens in a new tab)PMCIDPMC9237094 (opens in a new tab)DOI10.1038/s41598-022-14463-9 (opens in a new tab)PepBankPUB-35760980
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

The skin has a protective barrier against the external environment, making the transdermal delivery of active macromolecules very difficult. Cell-penetrating peptides (CPPs) have been accepted as useful delivery tools owing to their high transduction efficiency and low cytotoxicity. In this study, we evaluated the hydrophobic peptide, macromolecule transduction domain 1067 (MTD 1067) as a CPP for the transdermal delivery of protein cargoes of various sizes, including growth hormone-releasing hexapeptide-6 (GHRP-6), a truncated form of insulin-like growth factor-I (des(1-3)IGF-I), and platelet-derived growth factor BB (PDGF-BB). The MTD 1067-conjugated GHRP-6 (MTD-GHRP-6) was chemically synthesized, whereas the MTD 1067-conjugated des(1-3)IGF-I and PDGF-BB proteins (MTD-des(1-3)IGF-I and MTD-PDGF-BB) were generated as recombinant proteins. All the MTD 1067-conjugated cargoes exhibited biological activities identical or improved when compared to those of the original cargoes. The analysis of confocal microscopy images showed that MTD-GHRP-6, MTD-des(1-3)IGF-I, and MTD-PDGF-BB were detected at 4.4-, 18.8-, and 32.9-times higher levels in the dermis, respectively, compared to the control group without MTD. Furthermore, the MTD 1067-conjugated cargoes did not show cytotoxicity. Altogether, our data demonstrate the potential of MTD 1067 conjugation in developing functional macromolecules for cosmetics and drugs with enhanced transdermal permeability.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01LabNot a test of GHRP-6 aloneOther designActivity measurement

    In laboratory tests, MTD-conjugated cargoes including GHRP‑6 had identical or improved biological activities compared with original cargoes.

    In plain wordsIn lab tests, MTD-conjugated cargoes including GHRP‑6 had identical or improved activity compared with original cargoes.

    Peptide
    GHRP-6
    Outcome
    MixedBiological activity
    Study

    n: not reported in source

    Comparator
    Original cargoes
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    All the MTD 1067-conjugated cargoes exhibited biological activities identical or improved when compared to those of the original cargoes.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneOther designActivity measurement

    In laboratory tests, MTD-conjugated cargoes including des(1‑3)IGF-I had identical or improved biological activities compared with original cargoes.

    In plain wordsIn lab tests, MTD-conjugated cargoes including des(1‑3)IGF-I had identical or improved activity compared with original cargoes.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    MixedBiological activity
    Study

    n: not reported in source

    Comparator
    Original cargoes
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    All the MTD 1067-conjugated cargoes exhibited biological activities identical or improved when compared to those of the original cargoes.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  3. 03LabNot a test of GHRP-6 aloneOther designPharmacokinetics

    In microscopy tests, dermal MTD-GHRP‑6 levels were higher than GHRP‑6 levels without MTD.

    In plain wordsIn lab tests, more MTD-GHRP‑6 reached the dermis than GHRP‑6 without MTD.

    Peptide
    GHRP-6
    Outcome
    IncreaseDermal cargo levels
    Study

    n: not reported in source

    Comparator
    GHRP-6 without MTD
    Outcome group
    Pharmacokinetics · Skin and wound

    Measurements

    Relative dermal level
    4.4 fold
    MTD-GHRP-6 versus control without MTD

    Source sentences

    Summary
    The analysis of confocal microscopy images showed that MTD-GHRP-6, MTD-des(1-3)IGF-I, and MTD-PDGF-BB were detected at 4.4-, 18.8-, and 32.9-times higher levels in the dermis, respectively, compared to the control group without MTD.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 04LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneOther designPharmacokinetics

    In microscopy tests, dermal MTD-des(1‑3)IGF-I levels were higher than levels without MTD.

    In plain wordsIn lab tests, more MTD-des(1‑3)IGF-I reached the dermis than des(1‑3)IGF-I without MTD.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseDermal cargo levels
    Study

    n: not reported in source

    Comparator
    des(1-3)IGF-I without MTD
    Outcome group
    Pharmacokinetics · Skin and wound

    Measurements

    Relative dermal level
    18.8 fold
    MTD-des(1-3)IGF-I versus control without MTD

    Source sentences

    Summary
    The analysis of confocal microscopy images showed that MTD-GHRP-6, MTD-des(1-3)IGF-I, and MTD-PDGF-BB were detected at 4.4-, 18.8-, and 32.9-times higher levels in the dermis, respectively, compared to the control group without MTD.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  5. 05LabNot a test of GHRP-6 aloneOther designSafety outcome

    In laboratory tests, MTD-conjugated cargoes including GHRP‑6 showed no cytotoxicity.

    In plain wordsIn lab tests, MTD-conjugated cargoes including GHRP‑6 showed no cell toxicity.

    Peptide
    GHRP-6
    Outcome
    No significant changeCytotoxicity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Furthermore, the MTD 1067-conjugated cargoes did not show cytotoxicity.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  6. 06LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneOther designSafety outcome

    In laboratory tests, MTD-conjugated cargoes including des(1‑3)IGF-I showed no cytotoxicity.

    In plain wordsIn lab tests, MTD-conjugated cargoes including des(1‑3)IGF-I showed no cell toxicity.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeCytotoxicity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Furthermore, the MTD 1067-conjugated cargoes did not show cytotoxicity.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Versions 2 to 3

    21 Oct 2026, 13:52 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 12:50 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.